First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease

First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease

Abstract The combination of rifamycin (RFP), ethambutol (EB), and macrolides is currently the standard regimen for treatment of Mycobacterium avium complex pulmonary disease (MAC-PD). However, poor adherence to the standardized regimens recommended by current guidelines have been reported. We undert...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kiyoharu Fukushima, Seigo Kitada, Sho Komukai, Tomoki Kuge, Takanori Matsuki, Hiroyuki Kagawa, Kazuyuki Tsujino, Mari Miki, Keisuke Miki, Hiroshi Kida
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/3a2e1baa63ee4ff4a81f0ec6b2a4718d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares